Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Authors:
Open Access
- 2 August 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (3) , e531-e539
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific neutralizing antibodies (NAbs) in patients with COVID-19. Blood samples (n = 173) were collected from 30 patients with COVID-19 over a 3-month period after symptom onset and analyzed for SARS-CoV-2–specific NAbs using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. SARS-CoV-2–specific NAb titers were low for the first 7–10 days after symptom onset and increased after 2–3 weeks. The median peak time for NAbs was 33 days (interquartile range [IQR], 24–59 days) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR, 19.6–42.4%). NAb titers increased over time in parallel with the rise in immunoglobulin G (IgG) antibody levels, correlating well at week 3 (r = 0.41, P < .05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including stem cell factor (SCF), TNF-related apoptosis-inducing ligand (TRAIL), and macrophage colony-stimulating factor (M-CSF). These data provide useful information regarding dynamic changes in NAbs in patients with COVID-19 during the acute and convalescent phases.Keywords
All Related Versions
Funding Information
- Science and Technology Commission of Chongqing (cstc2020jscx-fyzx0053)
- Chongqing Medical University (CQMUNCP0302, CQMUNCP0304)
- Leading Talent Program of Chongqing Science and Technology Commission (CSTCCXLJRC201719)
- Major National Science and Technology Program (2017ZX10202203)
This publication has 25 references indexed in Scilit:
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B CellsCell, 2020
- COVID-19: Epidemiology, Evolution, and Cross-Disciplinary PerspectivesTrends in Molecular Medicine, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- The potential danger of suboptimal antibody responses in COVID-19Nature Reviews Immunology, 2020
- Convalescent plasma as a potential therapy for COVID-19The Lancet Infectious Diseases, 2020
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoVNature Communications, 2020
- Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patientsClinical Immunology, 2006
- A serological survey on neutralizing antibody titer of SARS convalescent seraJournal of Medical Virology, 2005
- Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear PhagocytesVirology, 1995
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990